Directors have fiduciary duties to implement and monitor AI governance systems, particularly when AI represents a mission-critical business risk, and under the Caremark doctrine, sustained or systematic oversight failures may expose them to personal liability. That is the warning Fenwick & West issues to corporate boards, and it reflects a broader consensus among governance experts: AI oversight is no longer optional board hygiene. The practical question for a director is not whether the duty exists, but whether the company's current governance would survive scrutiny. A structured diagnostic—covering strategy, risk assessment, accountability, transparency, and compliance—can turn that abstract legal exposure into a concrete agenda.
The Board's Evolving Fiduciary Duty in the Age of AI
Corporate law has long required board members to discharge fiduciary duties of care and loyalty, which require them to make informed decisions in the best interest of the company. As Robert Eccles wrote on the Harvard Law School Forum on Corporate Governance, current litigation trends indicate that directors are more likely to face personal liability for AI-supported mishaps as the potential impact on companies becomes clearer, much as they did in cybersecurity. Directors who fail to uphold their fiduciary duty and mitigate preventable harms from AI systems their companies deploy expose both the company and themselves to legal liability.
The National Association of Corporate Directors, working with the Data & Trust Alliance, frames the task as board readiness: with boards anticipating significant AI impact on their businesses, they must evaluate their own preparedness, understand the company's current engagement with AI, integrate AI into strategy and risk discussions, and leverage existing committees to oversee AI components where they are most appropriately governed. Boards do not need to become technical experts; they need enough information, advice, and expertise to ask the right questions and validate management's answers.





